Role of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in psychological stress and depression
PDF | HTML | How to cite
Metrics: PDF 1597 views | HTML 2594 views | ?
1Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan
2School of Medicine, National Yang-Ming University, Taipei, Taiwan
Shih-Jen Tsai, email: [email protected]
Keywords: brain-derived neurotrophic factor, tissue-type plasminogen activator, plasminogen activator inhibitor-1, major depressive disorder, stress
Received: May 30, 2017 Accepted: July 25, 2017 Published: August 04, 2017
Major depressive disorder is a common illness worldwide, but the pathogenesis of the disorder remains incompletely understood. The tissue-type plasminogen activator-plasminogen proteolytic cascade is highly expressed in the brain regions involved in mood regulation and neuroplasticity. Accumulating evidence from animal and human studies suggests that tissue-type plasminogen activator and its chief inhibitor, plasminogen activator inhibitor-1, are related to stress reaction and depression. Furthermore, the neurotrophic hypothesis of depression postulates that compromised neurotrophin brain-derived neurotrophic factor (BDNF) function is directly involved in the pathophysiology of depression. In the brain, the proteolytic cleavage of proBDNF, a BDNF precursor, to mature BDNF through plasmin represents one mechanism that can change the direction of BDNF action. We also discuss the implications of tissue-type plasminogen activator and plasminogen activator inhibitor-1 alterations as biomarkers for major depressive disorder. Using drugs that increase tissue-type plasminogen activator or decrease plasminogen activator inhibitor-1 levels may open new avenues to develop conceptually novel therapeutic strategies for depression treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.